“U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal”, January 29, 2019
PORTFOLIO
FACIT actively manages our diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development.
FUNDS
With critical seed funding, FACIT makes it possible for Ontario’s best cancer research discoveries to compete globally and reach patients.